Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 20498 | 1.1705 |
09:34 ET | 2668 | 1.17 |
09:36 ET | 3043 | 1.17 |
09:41 ET | 6800 | 1.17 |
09:43 ET | 1300 | 1.17 |
09:45 ET | 2100 | 1.165 |
09:48 ET | 600 | 1.165 |
09:50 ET | 100 | 1.17 |
09:54 ET | 100 | 1.165 |
09:56 ET | 100 | 1.16 |
09:59 ET | 400 | 1.1696 |
10:01 ET | 8400 | 1.18 |
10:03 ET | 100 | 1.18 |
10:10 ET | 200 | 1.175 |
10:12 ET | 5000 | 1.1799 |
10:14 ET | 500 | 1.17 |
10:15 ET | 4971 | 1.1799 |
10:17 ET | 4997 | 1.18 |
10:19 ET | 100 | 1.17 |
10:21 ET | 15346 | 1.17 |
10:24 ET | 100 | 1.175 |
10:26 ET | 200 | 1.17 |
10:28 ET | 200 | 1.17 |
10:30 ET | 200 | 1.17 |
10:32 ET | 200 | 1.17 |
10:39 ET | 100 | 1.18 |
10:50 ET | 2300 | 1.175 |
10:51 ET | 200 | 1.175 |
10:53 ET | 1300 | 1.17 |
10:55 ET | 300 | 1.1752 |
11:00 ET | 2000 | 1.1701 |
11:04 ET | 19399 | 1.165 |
11:06 ET | 670 | 1.165 |
11:08 ET | 2000 | 1.17 |
11:09 ET | 115 | 1.1652 |
11:11 ET | 6220 | 1.165 |
11:18 ET | 1000 | 1.165 |
11:29 ET | 800 | 1.17 |
11:42 ET | 100 | 1.17 |
11:47 ET | 142 | 1.16 |
11:49 ET | 5403 | 1.165 |
11:54 ET | 530 | 1.17 |
12:03 ET | 45723 | 1.17 |
12:05 ET | 30002 | 1.17 |
12:07 ET | 931 | 1.17 |
12:09 ET | 400 | 1.18 |
12:14 ET | 6000 | 1.18 |
12:18 ET | 100 | 1.18 |
12:21 ET | 5000 | 1.1799 |
12:27 ET | 6600 | 1.17 |
12:32 ET | 425 | 1.17 |
12:36 ET | 148 | 1.165 |
12:38 ET | 100000 | 1.165 |
12:39 ET | 1430 | 1.17 |
12:41 ET | 600 | 1.17 |
12:43 ET | 5800 | 1.175 |
12:50 ET | 1000 | 1.175 |
12:57 ET | 300 | 1.1716 |
01:01 ET | 300 | 1.1704 |
01:06 ET | 18955 | 1.18 |
01:08 ET | 4200 | 1.1804 |
01:12 ET | 200 | 1.18 |
01:14 ET | 1399 | 1.18 |
01:15 ET | 694 | 1.181 |
01:17 ET | 400 | 1.18 |
01:19 ET | 8236 | 1.18 |
01:30 ET | 300 | 1.17 |
01:33 ET | 427 | 1.1704 |
01:35 ET | 100 | 1.175 |
01:42 ET | 200 | 1.175 |
01:44 ET | 100 | 1.175 |
01:48 ET | 100 | 1.175 |
01:51 ET | 600 | 1.17 |
01:53 ET | 9164 | 1.17 |
01:55 ET | 1630 | 1.175 |
02:00 ET | 449 | 1.175 |
02:04 ET | 100 | 1.18 |
02:08 ET | 100 | 1.17 |
02:09 ET | 7200 | 1.18 |
02:15 ET | 100 | 1.18 |
02:26 ET | 1600 | 1.17 |
02:27 ET | 2000 | 1.175 |
02:33 ET | 100 | 1.17 |
02:38 ET | 350 | 1.17 |
02:44 ET | 250 | 1.175 |
02:45 ET | 100 | 1.17 |
02:47 ET | 1000 | 1.175 |
02:51 ET | 100 | 1.18 |
02:54 ET | 600 | 1.17 |
02:58 ET | 500 | 1.1711 |
03:00 ET | 100 | 1.17 |
03:05 ET | 300 | 1.175 |
03:07 ET | 100 | 1.175 |
03:12 ET | 100 | 1.175 |
03:14 ET | 400 | 1.18 |
03:16 ET | 100 | 1.175 |
03:18 ET | 2000 | 1.177 |
03:20 ET | 345 | 1.173 |
03:21 ET | 100 | 1.175 |
03:23 ET | 100 | 1.18 |
03:25 ET | 529 | 1.175 |
03:27 ET | 200 | 1.1799 |
03:30 ET | 400 | 1.175 |
03:32 ET | 200 | 1.18 |
03:34 ET | 1300 | 1.18 |
03:36 ET | 1100 | 1.175 |
03:38 ET | 20986 | 1.18 |
03:39 ET | 7717 | 1.1797 |
03:41 ET | 1305 | 1.18 |
03:43 ET | 14253 | 1.18 |
03:45 ET | 200 | 1.185 |
03:48 ET | 125 | 1.18 |
03:50 ET | 100 | 1.185 |
03:52 ET | 400 | 1.185 |
03:54 ET | 300 | 1.185 |
03:56 ET | 2740 | 1.19 |
03:57 ET | 6302 | 1.185 |
03:59 ET | 45822 | 1.2 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 93.7M | 8.8x | --- |
Spero Therapeutics Inc | 69.2M | 4.0x | --- |
Aytu Biopharma Inc | 17.0M | -1.1x | --- |
2Seventy Bio Inc | 245.1M | -1.6x | --- |
Fortress Biotech Inc | 38.8M | -0.4x | --- |
Nektar Therapeutics | 204.3M | -1.2x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $93.7M |
---|---|
Revenue (TTM) | $119.6M |
Shares Outstanding | 78.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.04 |
EPS | $0.14 |
Book Value | $-0.70 |
P/E Ratio | 8.8x |
Price/Sales (TTM) | 0.8 |
Price/Cash Flow (TTM) | 7.2x |
Operating Margin | 4.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.